Breaking News
Get 40% Off 0
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks
Close

CSPC Pharmaceutical Group Ltd (1093)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
6.61 +0.09    +1.38%
03:59:59 - Closed. Currency in HKD ( Disclaimer )
Type:  Equity
Market:  Hong Kong
ISIN:  HK1093012172 
  • Volume: 44,383,086
  • Bid/Ask: 6.60 / 6.62
  • Day's Range: 6.45 - 6.64
CSPC Pharma 6.61 +0.09 +1.38%

HK:1093 Financials

 
A brief overview of the HK:1093 financials. This summary provides an overview of the most significant critical numbers from each of its financial reports, including the income statement, balance sheet, and cash flow statement. Additionally, it features several financial ratios that provide insight into the company's financial health. Users can select to view data from four periods of either annual or quarterly information, allowing them to track financial performance of CSPC Pharmaceutical Group Ltd over time.

CSPC Pharmaceutical Group Limited reported earnings results for the full year ended December 31, 2023. For the full year, the company reported sales was CNY 31,450.11 million compared to CNY 30,936.9 million a year ago. Net income was CNY 5,873.33 million compared to CNY 6,091.39 million a year ago. Basic earnings per share from continuing operations was CNY 0.4947 compared to CNY 0.5111 a year ago. Diluted earnings per share from continuing operations was CNY 0.4947 compared to CNY 0.5111 a year ago.

AnnualQuarterly  
InvestingPro Advanced Financial Summary
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

1093 Income Statement

Gross margin TTM 70.51%
Operating margin TTM 22.31%
Net Profit margin TTM 18.68%
Return on Investment TTM 16.93%
 Total Revenue  Net Income
Period Ending: Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023
Total Revenue 7585.03 7784.66 8027.14 8053.27
Gross Profit 5384.59 5554.46 5719.04 5518.6
Operating Income 1789.64 1730.38 1735.73 1760.27
Net Income 1378.68 1527.65 1538.14 1428.84

1093 Balance Sheet

Quick Ratio MRQ 2.31
Current Ratio MRQ 2.63
LT Debt to Equity MRQ -
Total Debt to Equity MRQ 2.13%
 Total Assets  Total Liabilities
Period Ending: Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023
Total Assets 46282.17 43673.23
Total Liabilities 11264.16 10161.35
Total Equity 35018.01 33511.89 33511.89 31641.88

1093 Cash Flow Statement

Cash Flow/Share TTM 0
Revenue/Share TTM 2.65
Operating Cash Flow  0.00%
 Cash  Net Change in Cash
Period Ending: Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023
Period Length: 0 Months 0 Months 0 Months 0 Months
Cash From Operating Activities
Cash From Investing Activities
Cash From Financing Activities
Net Change in Cash
* In Millions of CNY (except for per share items)
InvestingPro
Go to Dashboard InvestingPro

Unlock access to over 1000 metrics with InvestingPro

View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.

 
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

1093 Comments

Write your thoughts about CSPC Pharmaceutical Group Ltd
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
JAME Megueni
VRAQ Aug 01, 2022 12:22AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Nomura Drops CSPC PHARMA TP to $11.14, Rating Buy
JAME Megueni
VRAQ May 25, 2022 10:08PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
C Suisse Axes CSPC PHARMA TP to $12, Rating Outperform
JAME Megueni
VRAQ Mar 22, 2022 11:07PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Nomura Raises CSPC PHARMA TP to $12.32, Rated Buy
JAME Megueni
VRAQ Dec 06, 2021 9:24PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
M Stanley Axes CSPC PHARMA TP to $12, Rated Overweight
JAME Megueni
VRAQ May 25, 2021 10:19PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Daiwa Downgrades CSPC PHARMA to ***Underperform,*** Lifts TP to $9.9
JAME Megueni
VRAQ May 24, 2021 10:56PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
C Suisse Ramps up CSPC PHARMA TP to $14; Rated ***Outperform***
JAME Megueni
VRAQ May 23, 2021 10:47PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
M Stanley Heightens CSPC PHARMA TP to $12.7; Rated ***Overweight***
JAME Megueni
VRAQ Mar 16, 2021 2:59AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Credit Suisse Lifts CSPC PHARMA  TP to $11.5 as Management Guides For Double-digit FY21 Rev. Growth
JAME Megueni
VRAQ Jan 27, 2021 9:39PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
HSBC Global Research Inches Down CSPC PHARMA (1093) TP to $14.3; ***Rated Buy***
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email